|
|
 |
|
Viewing report
|
|
|
|
Innovations and Pipelines for Respiratory Disorders: Niche Markets, New Products and Future Developments
Business Insights, Aug 2008, Pages: 145
Business Insights' portfolio of healthcare management reports is designed to help you make well informed and timely business decisions. We understand the problems facing today's pharmaceutical and healthcare executives when trying to drive your business forward, and appreciate the importance of accurate, up-to-date, incisive product, market and company analysis. We help you to crystallize your business decisions.
The strength of our research and analysis is derived from access to unparalleled databases and libraries of information and the use of proprietary analytic techniques. Business Insights reports are authored by independent experts and contain findings garnered from dedicated primary research. Our authors' leading positions secure them access to interview key executives and to establish which issues will be of greatest strategic significance for the industry. Our healthcare portfolio of reports can be used across a wide range of business functions to assess market conditions and devise future strategy.
Our reports cover key areas including strategy, industry analysis, market outlook, new business opportunities and strategic insight.
Some key findings from this report...
- The respiratory and pulmonary product market expanded at a CAGR of 9.3% over the period 2003-07. Growth has been most prominent in the sale of anti-asthma and COPD products, which accounted for 55% of global respiratory revenues in 2007.
- Anti-asthma and COPD treatments are predominantly comprised of innovative products, which accounted for 64.9% of total product revenues in 2007. Revenue growth in this category is being driven by the sale of both plain, inhaled anticholinergics and inhaled combination products (B2 stimulants and corticosteroids).
- GlaxoSmithKline is the global market leader for respiratory product sales. GSK’s dominance will be reinforced by a strong R&D portfolio that includes a number of phase II combination candidates.
- Research into treatments for cystic fibrosis are currently concentrated on methods of non-viral gene transfer. The successful launch of gene therapy innovatives is not expected until 2030.
- Real-time PCR is a significant development in the treatment of respiratory tract infections, allowing rapid/accurate pathogen identification through genotyping. This will create market potential for targeted, pathogen-specific first line anti-infective treatments.
The market for respiratory disorder treatments is continuing to experience rapid expansion as healthcare payors increasingly acknowledge the high treatment costs associated with chronic indications. A shift in developmental focus has become the driving force for market transformation, with research efforts now targeting the causative disease pathway in an effort to prevent symptom presentation and pathological decline. In the short term, a number of impending product launches will satisfy unmet demand within high-value market niches by addressing issues of patient compliance and targeting patients at the more severe end of the disease spectrum.
‘Innovations and Pipelines for Respiratory Disorders’ is a new report published by Business Insights that examines the future of the respiratory disorders market and explores the dynamics and drivers for current and emerging treatments. This report assesses leading mechanisms of action in drug development pipelines based upon clinical/preclinical results, potential market positioning and sales success in addition to identifying associated investment opportunities. The major trends and issues affecting new product development are highlighted and the future potential of leading innovations is evaluated. This report also identifies major areas of unmet market need and provides a detailed assessment of the currently marketed portfolios and developmental products of key companies within the sector.
Explore the latest trends and innovations in respiratory treatments, assess the performances of currently marketed medications and evaluate the potential of leading pipeline candidates with this report...
Top five reasons to order your copy today
- Assess patient potential, treatment trends and sales patterns across the global respiratory market with this report’s analysis of countries including Japan, France, Germany, Italy, Spain, the UK and the US.
- Discover which respiratory indications have the greatest potential to provide franchise growth and profile the key drivers of growth and innovation across Asthma, COPD, Cystic Fybrosis, Pulmonary Hypertension, Respiratory Allergies and Respiratory tract infections.
- Compare the product pipelines, therapy area investments and growth metrics of key players in the respiratory disorders market with this report’s assessment of major companies including GSK, Merck & Co., Boehringer Ingelheim, and AstraZeneca.
- Examine the major unmet needs within the global respiratory disorders market, identify the latest key events and understand the most important issues affecting major companies within this sector.
- Evaluate leading mechanisms of action under development and discover which have the potential to fill current market niches, with this report’s analysis of clinical/preclinical results, potential market positioning, sales performance and investment activity.
Key issues examined in this report...
- Shifting R&D focus. The majority of currently marketed therapies are aimed at treating presenting symptomology, however new disease models have identified biomarkers involved in pathological disease progression which may act as targets for pipeline drug candidates.
- Increased regulatory scrutiny. Stringent analysis of datasets and increased requirements for dataset submission has put pressure on drug developers to focus their pipelines around leading candidates.
- Drive for innovation. The success of leading companies is heavily reliant upon a small number of branded products (eg. Singular accounts for 99.86% of Merck & Co's respiratory portfolio revenues). Many leading players are now aiming to expand their portfolios by developing new drug candidates with novel mechanisms.
- COPD/Asthma development potential. The most significant opportunities for drug developers remain within the COPD and asthma patient populations, where present treatment regimens are largely inadequate and convenient dosing regimens are required.
Your questions answered...
- What are the leading existing marketed innovatives and how has their success been achieved?
- What are the most exciting compounds currently in development for the different respiratory disease indications?
- What is the forecast sales potential of these products?
- How will novel products be positioned to maximize their potential?
- How do the product pipelines of leading respiratory companies compare and what are their investment and growth strategies?
- What are the differences between the treatment models of leading companies in terms of clinical development?
- Which companies are best positioned to succeed over 2008-12 based on their pipeline clinical candidates?
Product samples
A sample for this product is available. Please Login/Register to download this sample.
Customers who bought this item also bought
World Market for Addiction Disorders, 2009–2016, The Future Therapies for Substance Dependence and Impulse Control
Biotechnology 2006: Winning Companies and Pipelines
The World Market for Gynaecology, 2007-2017
Antiageing and Life Enhancement Pharmacotherapeutics: Rejuvenating Drug Markets To 2012 and Beyond
The Lifestyle Drugs Outlook To 2007: Challenges And Opportunities In A High-Profile Growth Market
The Eastern European Pharmaceutical Market Outlook To 2014: Policy Environment, Market Structure, Competitive Landscape, Growth Opportunities
Probiotic Market- Advanced Technologies and Global Market (2009 - 2014)
Monoclonal Antibody Therapies: Evolving Into A $30 Billion Market
Delivering RNAi-Based Therapeutics & Diagnostics: Challenges & Opportunities
Antibody Therapeutics: Production, Clinical Trials, and Strategic Issues
|
|
|
|
